Changing face of vaccination in immunocompromised hosts

Current Infectious Disease Reports

Volumn 16, Issue 9, 2014, Pages

  O'Shea, Daire ^a,b   Widmer, Lukas A ^c,d   Stelling, Jörg ^c,d   Egli, Adrian ^e,f  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ETH ZURICH   (Switzerland)

^d SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Computational models; Immunomodulation; Individualized vaccine strategies; Mathematical models; Surrogates of vaccine efficacy; Systems biology; Transplant recipients; Vaccination

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; DENDRITIC CELL; DRUG SAFETY; GENETIC RISK; GRAFT RECIPIENT; HELPER CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA VACCINATION; INNATE IMMUNITY; MATHEMATICAL MODEL; ORGAN TRANSPLANTATION; PERSONALIZED MEDICINE; REVIEW; SEROCONVERSION; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID ORGAN TRANSPLANTATION; SYSTEMS BIOLOGY; T FOLLICULAR HELPER CELL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; VACCINATION;

EID: 84906100979     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-014-0420-2     Document Type: Review

References (123)

1. Kumar D, Michaels MG, Morris MI, Green M, Avery RK, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis. 2010;10:521-6.
2. Memoli MJ, Athota R, Reed S, Czajkowski L, Bristol T, et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis. 2014;58:214-24.
3. Centers for Disease C, Prevention. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices-United States, 2013-2014. MMWR Recomm Rep. 2013;62:1-43.
4. Chemaly RF, Vigil KJ, Saad M, Vilar-Compte D, Cornejo-Juarez P, et al. A multicenter study of pandemic influenza A (H1N1) infection in patients with solid tumors in 3 countries: early therapy improves outcomes. Cancer. 2012;118:4627-33.
5. Cordero E, Aydillo T, Farinas MC, Pano-Pardo JR, Pachon J, et al. Immunosuppressed patients with pandemic influenza A 2009 (H1N1) virus infection. Eur J Clin Microbiol Infect Dis. 2012;31:547-56.
6. Hur SJ, Kim DH, Chun SC, Lee SK. Effect of adenovirus and influenza virus infection on obesity. Life Sci. 2013;93:531-5.
7. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9:493-504.
8. Minnema BJ, Husain S, Mazzulli T, Hosseini-Mogaddam SM, Patel M, et al. Clinical characteristics and outcome associated with pandemic (2009) H1N1 influenza infection in patients with hematologic malignancies: a retrospective cohort study. Leuk Lymphoma. 2013;54:1250-5.
9. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335 -47.
10. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, et al. Updated international consensus guidelines on themanagement of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96:333-60.
11. Casanova JL, Abel L. The genetic theory of infectious diseases: a brief history and selected illustrations. Annu Rev Genomics Hum Genet. 2013;14:215-43.
12. Finco O, Rappuoli R. Designing Vaccines for the Twenty-First Century Society. Front Immunol. 2014;5:12.
13. Lombard M, Pastoret PP, Moulin AM. A brief history of vaccines and vaccination. Rev Sci Tech. 2007;26:29-48. (Pubitemid 47148811)
14. General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60:1-64.
15. .• Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. Clin Infect Dis. 2014;58:309-18. This paper summarizes important recommendations for vaccination of immunocompromised hosts.
16. Chon WJ, Kadambi PV, Harland RC, Thistlethwaite JR,West BL, et al. Changing attitudes toward influenza vaccination in U.S. Kidney transplant programs over the past decade. Clin J Am Soc Nephrol. 2010;5:1637-41.
17. Eckerle I, Rosenberger KD, Zwahlen M, Junghanss T. Serologic vaccination response after solid organ transplantation: a systematic review. PLoS One. 2013;8:e56974.
18. Henn AD, Wu S, Qiu X, Ruda M, Stover M, et al. High-resolution temporal response patterns to influenza vaccine reveal a distinct human plasma cell gene signature. Sci Rep. 2013;3:2327.
19. Obermoser G, Presnell S, Domico K, Xu H, Wang Y, et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity. 2013;38:831-44.
20. Clifford HD, Yerkovich ST, Khoo SK, Zhang G, Upham J, et al. TLR3 and RIG-I gene variants: associations with functional effects on receptor expression and responses to measles virus and vaccine in vaccinated infants. Hum Immunol. 2012;73:677-85.
21. .• Grzegorzewska AE, Pajzderski D, Sowinska A, Mostowska A, Jagodzinski PP. IL4R and IL13 polymorphic variants and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to HBV vaccination or infection. Vaccine. 2013;31:1766-70. This work highlights the impact of single nucleotide polymorphisms in the Th2 signaling cascade, influencing the antibody production to hepatitis B virus.
22. Ovsyannikova IG, Haralambieva IH, Kennedy RB, Pankratz VS, Vierkant RA, et al. Impact of cytokine and cytokine receptor gene polymorphisms on cellular immunity after smallpox vaccination. Gene. 2012;510:59-65.
23. Ovsyannikova IG, Kennedy RB, O'Byrne M, Jacobson RM, Pankratz VS, et al. Genome-wide association study of antibody response to smallpox vaccine. Vaccine. 2012;30:4182-9.
24. Pajewski NM, Shrestha S, Quinn CP, Parker SD, Wiener H, et al. A genome-wide association study of host genetic determinants of the antibody response to Anthrax Vaccine Adsorbed. Vaccine. 2012;30:4778-84.
25. White SJ, Haralambieva IH, Ovsyannikova IG, Vierkant RA, O'Byrne MM, et al. Replication of associations between cytokine and cytokine receptor single nucleotide polymorphisms and measles-specific adaptive immunophenotypic extremes. Hum Immunol. 2012;73:636-40.
26. Yucesoy B, Talzhanov Y, Johnson VJ, Wilson NW, Biagini RE, et al. Genetic variants within the MHC region are associated with immune responsiveness to childhood vaccinations. Vaccine. 2013;31:5381-91.
27. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol. 2009;9:185-94.
28. Liu WM, van der Zeijst BA, Boog CJ, Soethout EC. Aging and impaired immunity to influenza viruses: implications for vaccine development. Hum Vaccin. 2011;7(Suppl):94-8.
29. Sambhara S, McElhaney JE. Immunosenescence and influenza vaccine efficacy. Curr Top Microbiol Immunol. 2009;333:413-29.
30. Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol. 2008;8:737-44.
31. Kirsch S, Thijssen S, Alarcon Salvador S, Heine GH, van Bentum K, et al. T-cell numbers and antigen-specific T-cell function follow different circadian rhythms. J Clin Immunol. 2012;32:1381-9.
32. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med. 2004;351:2295-301. (Pubitemid 39552745)
33. Egli A, Santer D, Barakat K, Zand M, Levin A, et al. Vaccine adjuvants - understanding molecular mechanisms to improve vaccines. Swiss Medical Weekly in press. 2014.
34. Salles MJ, Sens YA, Boas LS, Machado CM. Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs. Clin Transpl. 2010;24:E17-23.
35. Eickenberg S, Mickholz E, Jung E, Nofer JR, Pavenstadt HJ, et al. Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus. Arthritis Res Ther. 2012;14:R110.
36. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47:401-9.
37. Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol. 2006;6:231-43. (Pubitemid 43290992)
38. Kwong PD,Mascola JR, Nabel GJ. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol. 2013;13:693-701.
39. Sun J, Kudahl UJ, Simon C, Cao Z, Reinherz EL, et al. Largescale analysis of B-cell epitopes on influenza virus hemagglutinin - implications for cross-reactivity of neutralizing antibodies. Front Immunol. 2014;5:38.
40. McCullers JA, Huber VC. Correlates of vaccine protection from influenza and its complications. Hum Vaccin Immunother. 2012;8:34-44.
41. DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine. 2012;31:49-57.
42. Sasaki S, Holmes TH, Albrecht RA, Garcia-Sastre A, Dekker CL, et al.Distinct cross-reactive B-cell responses to live attenuated and inactivated influenza vaccines. J Infect Dis. 2014.
43. Dormitzer PR, Galli G, Castellino F, Golding H, Khurana S, et al. Influenza vaccine immunology. Immunol Rev. 2011;239:167-77.
44. Bridevaux PO, Aubert JD, Soccal PM, Mazza-Stalder J, Berutto C, et al. Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study. Thorax. 2014;69:32-8.
45. Ng BJ, Glanville AR, Snell G, Musk M, Holmes M, et al. The impact of pandemic influenza A H1N1 2009 on Australian lung transplant recipients. Am J Transplant. 2011;11:568-74.
46. Vu DL, Bridevaux PO, Aubert JD, Soccal PM, Kaiser L. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant. 2011;11:1071-8.
47. Danziger-Isakov L, Kumar D, Practice ASTIDCo. Vaccination in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:311-7.
48. Kumar D, Blumberg EA, Danziger-Isakov L, Kotton CN, Halasa NB, et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant. 2011;11:2020-30.
49. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:36-44.
50. Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken). 2011;63:1062-7.
51. Haller W, Buttery J, Laurie K, Beyerle K, Hardikar W, et al. Immune response to pandemic H1N1 2009 influenza a vaccination in pediatric liver transplant recipients. Liver Transpl. 2011;17:914-20.
52. Khazeni N, Hutton DW, Garber AM, Hupert N, Owens DK. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med. 2009;151:829-39.
53. Baluch A, Humar A, Eurich D, Egli A, Liacini A, et al. Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. Am J Transplant. 2013;13:1026-33.
54. Alam S, Knowlden ZA, Sangster MY, Sant AJ. CD4 T Cell Help Is Limiting and Selective during the Primary B Cell Response to Influenza Virus Infection. J Virol. 2014;88:314-24.
55. Liu Z, Fan H, Jiang S. CD4(+) T-cell subsets in transplantation. Immunol Rev. 2013;252:183-91.
56. McElhaney JE, Coler RN, Baldwin SL. Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults. Expert Rev Vaccines. 2013;12:759-66.
57. Ramirez LA, Daniel A, Frank I, Tebas P, Boyer JD. Seroprotection of HIV-Infected Subjects After Influenza A(H1N1) Vaccination Is Directly Associated With Baseline Frequency of Naive T Cells. J Infect Dis. 2014.
58. Paul WE, Ohara J. B-cell stimulatory factor-1/interleukin 4. Annu Rev Immunol. 1987;5:429-59.
59. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145-73. (Pubitemid 19138011)
60. Adler-Moore J, Munoz M, Kim H, Romero J, Tumpey T, et al. Characterization of themurine Th2 response to immunization with liposomal M2e influenza vaccine. Vaccine. 2011;29:4460-8.
61. Chakarov S, Fazilleau N. Monocyte-derived dendritic cells promote T follicular helper cell differentiation. EMBO Mol Med. 2014.
62. .•• Cubas RA, Mudd JC, Savoye AL, Perreau M, van Grevenynghe J, et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med. 2013;19:494-9. This paper highlights the crucial impact of T follicular cells on B-cell immunity.
63. Pallikkuth S, Parmigiani A, Silva SY, George VK, Fischl M, et al. Impaired peripheral blood T-follicular helper cell function in HIV-infected nonresponders to the 2009 H1N1/09 vaccine. Blood. 2012;120:985-93.
64. Rasheed MA, Latner DR, Aubert RD, Gourley T, Spolski R, et al. Interleukin-21 is a critical cytokine for the generation of virus-specific long-lived plasma cells. J Virol. 2013;87:7737-46.
65. Mazzone PJ, Mossad SB, Mawhorter SD, Mehta AC, Mauer JR. Cell-mediated immune response to influenza vaccination in lung transplant recipients. J Heart Lung Transplant. 2004;23:1175-81. (Pubitemid 39346234)
66. Candon S, Thervet E, Lebon P, Suberbielle C, Zuber J, et al. Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant. 2009;9:2346-54.
67. Sanchez-Fructuoso AI, Prats D, Naranjo P, Fernandez-Perez C, Gonzalez MJ, et al. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine. Transplantation. 2000;69:436-9. (Pubitemid 30118129)
68. Scharpe J, Evenepoel P, Maes B, Bammens B, Claes K, et al. Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant. 2008;8:332-7.
69. Heidt S, Roelen DL, Eijsink C, van Kooten C, Claas FH, et al. Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. Transplantation. 2008;86:1292-300.
70. Cordero E, Perez-Ordonez A, Aydillo TA, Torre-Cisneros J, Gavalda J, et al. Therapy with m-TOR inhibitors decreases the response to the pandemic influenza A H1N1 vaccine in solid organ transplant recipients. Am J Transplant. 2011;11:2205-13.
71. Egli A, Kohli S, Dickenmann M, Hirsch HH. Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. Transplantation. 2009;88:1161-8.
72. Heinschink A, Raab M, Daxecker H, Griesmacher A, Muller MM. In vitro effects of mycophenolic acid on cell cycle and activation of human lymphocytes. Clin Chim Acta. 2000;300:23-8. (Pubitemid 30665771)
73. .• Karnell JL, Karnell 3rd FG, Stephens GL, Rajan B, Morehouse C, et al. Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation. J Immunol. 2011;187:3603-12. Mycophenolic acid is a important factor of seroconversion. This paper explores the impact of Mycohenolic acid on B-cell functions.
74. Egli A, Kumar D, Broscheit C, O'Shea D, Humar A. Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. Transplantation. 2013;95:448-55.
75. Dorrington MG, Bowdish DM. Immunosenescence and novel vaccination strategies for the elderly. Front Immunol. 2013;4:171.
76. Cadeddu C, DeWaure C, Gualano MR, Di Nardo F, Ricciardi W. 23-valent pneumococcal polysaccharide vaccine (PPV23) for the prevention of invasive pneumococcal diseases (IPDs) in the elderly: is it really effective? J Prev Med Hyg. 2012;53:101-3.
77. Chen WH, Kozlovsky BF, Effros RB, Grubeck-Loebenstein B, Edelman R, et al. Vaccination in the elderly: an immunological perspective. Trends Immunol. 2009;30:351-9.
78. Cooper C, Thorne A, Klein M, Conway B, Boivin G, et al. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One. 2011;6:e17758.
79. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009;200:172-80.
80. Dhedin N, Krivine A, Le Corre N, Mallet A, Lioure B, et al. Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients. Vaccine. 2014;32:585-91.
81. Manuel O, Pascual M, Hoschler K, Giulieri S, Alves D, et al. Humoral response to the influenza A H1N1/09monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis. 2011;52:248-56.
82. Danziger-Isakov L, Cherkassky L, Siegel H, McManamon M, Kramer K, et al. Effects of influenza immunization on humoral and cellular alloreactivity in humans. Transplantation. 2010;89:838-44.
83. Katerinis I, Hadaya K, Duquesnoy R, Ferrari-Lacraz S, Meier S, et al. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant. 2011;11:1727-33.
84. Brakemeier S, Schweiger B, Lachmann N, Glander P, Schonemann C, et al. Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix((R))) in renal transplant recipients. Nephrol Dial Transplant. 2012;27:423-8.
85. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine. 2011;29:5145-52.
86. Wang TT, Tan GS, Hai R, Pica N, Ngai L, et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A. 2010;107:18979-84.
87. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10:787-96.
88. Garcia-Sastre A, Mena I. Novel vaccine strategies against emerging viruses. Curr Opin Virol. 2013;3:210-6.
89. Ulmer JB, Mason PW, Geall A, Mandl CW. RNA-based vaccines. Vaccine. 2012;30:4414-8.
90. Haralambieva IH, Oberg AL, Ovsyannikova IG, Kennedy RB, Grill DE, et al. Genome-wide characterization of transcriptional patterns in high and low antibody responders to rubella vaccination. PLoS One. 2013;8:e62149.
91. Kennedy RB, Ovsyannikova IG, Pankratz VS, Haralambieva IH, Vierkant RA, et al. Genome-wide genetic associations with IFNgamma response to smallpox vaccine. Hum Genet. 2012;131:1433-51.
92. Davis NA, Crowe Jr JE, Pajewski NM, McKinney BA. Surfing a genetic association interaction network to identify modulators of antibody response to smallpox vaccine. Genes Immunol. 2010;11:630-6.
93. Fellay J, Frahm N, Shianna KV, Cirulli ET, Casimiro DR, et al. Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial. J Infect Dis. 2011;203:773-9.
94. Png E, Thalamuthu A, Ong RT, Snippe H, Boland GJ, et al. A genome-wide association study of hepatitis B vaccine response in an Indonesian population reveals multiple independent risk variants in the HLA region. Hum Mol Genet. 2011;20:3893-8.
95. Miller EK, Dumitrescu L, Cupp C, Dorris S, Taylor S, et al. Atopy history and the genomics of wheezing after influenza vaccination in children 6-59 months of age. Vaccine. 2011;29:3431-7.
96. .• Haralambieva IH, Ovsyannikova IG, Kennedy RB, Vierkant RA, Pankratz VS, et al. Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination. Vaccine. 2011;29:7883-95. This paper explores a wide array of single nucleotide polymorphisms associated with the vaccine response to measles vaccination.
97. Umlauf BJ, Haralambieva IH, Ovsyannikova IG, Kennedy RB, Pankratz VS, et al. Associations between demographic variables and multiple measles-specific innate and cell-mediated immune responses after measles vaccination. Viral Immunol. 2012;25:29-36.
98. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138:1338-1345, 1345 e1331-1337.
99. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance. Nature. 2009;461:399-401.
100. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798-801.
101. Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, et al. IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med. 2011;3:348-61.
102. Dai J, Megjugorac NJ, Gallagher GE, Yu RY, Gallagher G. IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood. 2009;113:5829-38.
103. Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, et al. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immunol. 2007;8:254-61. (Pubitemid 46679436)
104. • Buonaguro L, Wang E, Tornesello ML, Buonaguro FM, Marincola FM. Systems biology applied to vaccine and immunotherapy development. BMC Syst Biol. 2011;5:146. In this paper, system biological aspects applied to vaccine development are explored.
105. Chen J, Wang Y, Guo D, Shen B. A systems biology perspective on rational design of peptide vaccine against virus infections. Curr Top Med Chem. 2012;12:1310-9.
106. Ozdemir V, Pang T, Knoppers BM, Avard D, Faraj SA, et al. Vaccines of the 21st century and vaccinomics: data-enabled science meets global health to spark collective action for vaccine innovation. OMICS. 2011;15:523-7.
107. Nakaya HI, Li S, Pulendran B. Systems vaccinology: learning to compute the behavior of vaccine induced immunity. Wiley Interdiscip Rev Syst Biol Med. 2012;4:193-205.
108. Mayer H, Zaenker KS, An Der Heiden U. A basic mathematical model of the immune response. Chaos. 1995;5:155-61.
109. Callard R, Hodgkin P. Modeling T- and B-cell growth and differentiation. Immunol Rev. 2007;216:119-29. (Pubitemid 46426518)
110. Palsson S, Hickling TP, Bradshaw-Pierce EL, Zager M, Jooss K, et al. The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models. BMC Syst Biol. 2013;7:95.
111. Dobrovolny HM, Reddy MB, Kamal MA, Rayner CR, Beauchemin CA. Assessing mathematical models of influenza infections using features of the immune response. PLoS One. 2013;8:e57088.
112. .•• Chakraborty AK, Das J. Pairing computation with experimentation: a powerful coupling for understanding T cell signalling. Nat Rev Immunol. 2010;10:59-71. This hallmark paper summarizes the computational aspects of T-cell signaling.
113. .• Maiwald T, Schneider A, Busch H, Sahle S, Gretz N, et al. Combining theoretical analysis and experimental data generation reveals IRF9 as a crucial factor for accelerating interferon -induced early antiviral signalling. FEBS J. 2010;277:4741-54. This paper describes in detail the computational aspects of the innate immune signaling cascade of interferon alpha signaling.
114. Smieja J, Jamaluddin M, Brasier AR, Kimmel M. Model-based analysis of interferon-beta induced signaling pathway. Bioinformatics. 2008;24:2363-9.
115. Kossow C, Jose D, Jaster R, Wolkenhauer O, Rateitschak K. Mathematical modelling unravels regulatory mechanisms of interferon-gamma-induced STAT1 serine-phosphorylation and MUC4 expression in pancreatic cancer cells. IET Syst Biol. 2012;6:73-85.
116. Cohen IR. Real and artificial immune systems: computing the state of the body. Nat Rev Immunol. 2007;7:569-74. (Pubitemid 46987782)
117. Goldstein B, Faeder JR, Hlavacek WS. Mathematical and computational models of immune-receptor signalling. Nat Rev Immunol. 2004;4:445-56. (Pubitemid 38745556)
118. Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol. 2011;12:786-95.
119. Diercks A, Aderem A. Systems approaches to dissecting immunity. Curr Top Microbiol Immunol. 2013;363:1-19.
120. Shen-Orr SS, Furman D. Variability in the immune system: of vaccine responses and immune states. Curr Opin Immunol. 2013;25:542-7.
121. Eissing T, Kuepfer L, Becker C, Block M, Coboeken K, et al. A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front Physiol. 2011;2:4.
122. Lindstrom ML, Bates DM. Nonlinear mixed effects models for repeated measures data. Biometrics. 1990;46:673-87. (Pubitemid 20333602)
123. Plan EL, Maloney A, Mentre F, Karlsson MO, Bertrand J. Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models. AAPS J. 2012;14:420-32.